Merck Serono, Domain develop drugs for neurodegenerative diseases; terminated
Merck Serono SA and Domain Therapeutics SA (GPCR drug discovery) have signed a deal to develop metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator (PAM) candidates for Parkinson’s disease and other neurodegenerative conditions.
- Drug Discovery Technologies
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.